Bibliographical noteFunding Information:
The work was supported by a grant (project ID Z99 CL999999) from the Intramural Research Program of the NIH Clinical Center.
The organizing committee thanks CBER Director Dr. Marks and OBRR Director Dr. Verdun for their constant support and providing direction to the committee. Dr. Flegel thanks Harvey Gordon Klein, MD, for review of the manuscript and comments and acknowledges the late Sherry Lynne Sheldon, MT(ASCP)SBB, whose contribution as laboratory supervisor in the Laboratory Services Section was critical for efficiently implementing the technology in a timely manner under fiscal constraints. PRT PLTs remain S.L. Sheldon's legacy to the patients and their safety at the NIH Clinical Center. Dr. Benjamin acknowledges that INTERCEPT RBCs are being developed under contract with the Biomedical Advanced Research and Development Authority, a division of the Department of Health and Human Services. SK is a consultant to Cerus, manufacturer of the Intercept system and serves on Medical Advisory Board of Creative Testing Solutions (CTS). ES is PI for the Cerus PIPER Phase IV clinical study at the Yale site?he receives no personal remuneration. SR has nothing to disclose. WF states that the views expressed do not necessarily represent the view of the National Institutes of Health, the Department of Health and Human Services, or the US Federal Government and no financial relationship relevant for this publication. RB is an employee and stockholder in Cerus Corporation, a manufacturer of pathogen reduction technologies. AR is an employee of Terumo BCT.